Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 31, 2001 - Issue 1
45
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Lack of interaction between bropirimine and 5-fluorouracil on human dihydropyrimidine dehydrogenase

, , &
Pages 25-31 | Published online: 22 Sep 2008

References

  • BRADFORD, M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248–254.
  • DESGRANGES, C., RAZAKA, G., CLERCQ, E. D., HARDEWIJIN, P., BALZARINI, J., DROUILLET, F. and BRICAUD, H., 1986, Effect of (E)-5-(2-bromovinyl)uraci on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Research, 46, 1094–1104.
  • ETIENNE, M. C., LAGRANGE, J. L., DASSONVILLE, 0., FLEMING, R., THYSS, A., RENNE, N., SCHNEIDER, M., DEMARD, F. and MILANO, G., 1994, Population study of dihydropyrimidine dehydrogenase in cancer patients. Journal of Clinical Oncology, 12, 2248–2253.
  • FLEMING, R. A., MILANO, G., THYSS, A., ETIENNE, M. C., RENEE, N., SCHNEIDER, M. and DEMARD, F., 1992, Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Research, 52, 2899–2902.
  • HAUER, M. J., THORNBURGH, B. A., EAGERNESS, P. E., WIENKERS, L. C., VRBANAC, J. J. and WICKREMA SINHA, A. J., 1997, Identification of the major urinary metabolites of bropirimine following oral administration of ["C] bropirimine to healthy human volunteers. Presented at the 8th North American ISSX Meeting (Abstract 219), October, South Carolina.
  • Lu, Z.-H., ZHANG, R. and DIASIO, R. B., 1992, Purification and characterization of dihydropyrimidine dehydrogenase from human liver. Journal of Biological Chemistry, 267, 17102–17109.
  • Lu, Z., ZHANG, R. and DIASIO, R. B., 1995, Population characterization of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clinical Pharmacology and Therapeutics, 58, 512–522.
  • MCMURROUGH, J. and McLEop, H. L., 1996, Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. British Journal of Clinical Pharmacology, 41, 425–427.
  • MILANO, G., ETIENNE, M. C., CASSUTO-VIGUIER, E., THYSS, A., SANTINI, J., FRENAY, M., RENEE, N., SCHNEIDER, M. and DEMARD, F., 1992, Influence of sex and age on fluorouracil clearance. Journal of Clinical Oncology, 10, 1171–1175.
  • NAGUIB, F. N. M., KOUNI, M. H. and CHA, S., 1989, Structure-activity relationship of ligands of dihydrouracil dehydrogenase from mouse liver. Biochemical Pharmacology, 38, 1471–1480.
  • OGURA, K., NISHIYAMA, T., TAKUBO, H., KATO, A., OKUDA, H., ARAKAWA, K., FUKUSHIMA, M., NAGAYAMA, S., KAWAGUCHI, Y. and WATABE, T., 1998, Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5 -(2-bromovinyl)uraci derived from the antiviral, sorivudine. Cancer Letters, 122, 107–113.
  • PHARMACEUTICAL AFFAIRS BUREAU, JAPANESE MINISTRY OF HEALTH AND WELFARE, 1994, A Report on Investigation of Side Effects of Sorivudine: Deaths Caused by Interaction Between Sorivudine and 5 - FU Prod rugs [in Japanese].
  • PORTER, D. J. T., CHESTNUT, W. G., TAYLOR, L. C. E., MERRIL, B. M. and SPECTOR, T., 1991, Inactivation of dihydropyrimidine dehydrogenase by 5 -iodouracil. journa/ of Biological Chemistry, 266, 19988–19994.
  • PORTER, D. J. T., CHESTNUT, W. G., MERRIL, B. M. and SPECTOR, T., 1992, Mechanism-based OR inactivation of dihydropyrimidine dehydrogenase by 5 -ethynyluracil. Journal of Biological Chemistry, 267, 5236–5242.
  • SKULNICK, H. I., WEED, S. D., EIDSON, E. E., RENIS, H. E., WIERENGA, W. and STRINGFIELD, D. A., 1985, Pyrimidinones. 1: 2-Amino-5-halo-6-aryl-4(3H)-pyrimidinones Interferon-inducing anti-viral agents. journal of Medicinal Chemistry, 28, 1864–1869.
  • SWINBANKS, D., 1994, Death bring clinical trials under scrutiny in Japan. Nature, 369, 697.
  • WIERENGA, W., 1985, Antiviral and other bioactivities of pyrimidinones. Pharmacology and Therapeutics, 30, 67–89.
  • WOODCOCK, T. M., MARTIN, D. S., DAMIN, L. E. M., KEMENY, N. E. and YOUNG, C. W., 1979, Combination clinical trials with thymidine and fluorouracil: A phase I and clinical phar-macological evaluation. Cancer, 45, 1135–1143.
  • WYNALDA, M. A., HAUER, M. J. and WIENKERS, L. C., 1998, Human biotransformation of bropirimine: Characterization of the major bropirimine oxidative metabolites formed in vitro. Drug Metabolism and Disposition, 26, 1048–1051.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.